Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM5U1LN)

Drug Name
aloisine A Drug Info
Synonyms
ALOISINE A; 4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol; 496864-16-5; RP107; 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE; CHEMBL75680; 7-n-Butyl-6-(4-hydroxyphenyl)[5H]pyrrolo[2,3-b]pyrazine; RP-107; ALH; 4-{7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl}phenol; 1ung; SCHEMBL80147; BDBM7377; GTPL5924; AC1NS169; 4-(7-Butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol; CHEBI:93641; CTK8D4068; DTXSID30416115; HMS3229A14; RM-39; BCP26893; ZINC2540737; ACT06534; IN1539; HSCI1_000219; MFCD04973541; AKOS005145972; CCG-206814; DB07364; RTC-063070; AJ-39131
Cross-matching ID
PubChem CID
448912
ChEBI ID
CHEMBL75680
CAS Number
CAS 496864-16-5
TTD Drug ID
D02XHC

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Fructose and mannose metabolism 1.96 2.08e-2 30/33 (90.91%) PFKL;GMDS;PFKP;...
Staphylococcus aureus infection 1.96 1.04e-2 72/95 (75.79%) CFH;CFB;C3;...
ECM-receptor interaction 1.89 2.08e-2 80/88 (90.91%) THBS2;COL9A3;THBS1;...
Galactose metabolism 1.81 3.65e-2 26/31 (83.87%) PFKL;GAA;PFKP;...
Complement and coagulation cascades 1.73 4.46e-2 76/85 (89.41%) CFH;CD59;F12;...
Autoimmune thyroid disease 1.73 4.17e-2 46/53 (86.79%) HLA-DPB1;HLA-DPA1;CGA;...
DNA replication 1.72 3.70e-2 34/36 (94.44%) LIG1;PCNA;RFC4;...
Type I diabetes mellitus 1.72 3.44e-2 38/43 (88.37%) PTPRN2;HLA-DPB1;HLA-DPA1;...
Allograft rejection 1.69 4.64e-2 32/38 (84.21%) HLA-DPB1;HLA-DPA1;HLA-B;...
Viral protein interaction with cytokine and cytokine re... 1.68 4.69e-2 84/100 (84%) CXCL14;CXCL9;ACKR3;...
Aldosterone synthesis and secretion -1.77 2.87e-2 85/98 (86.73%) CAMK2G;CALML5;LDLR;...
Cortisol synthesis and secretion -1.78 3.19e-2 58/65 (89.23%) CYP17A1;PBX1;CACNA1I;...
Steroid biosynthesis -1.84 2.87e-2 19/20 (95%) CYP24A1;HSD17B7;LSS;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H